• LAST PRICE
    3.6700
  • TODAY'S CHANGE (%)
    Trending Up0.0600 (1.6620%)
  • Bid / Lots
    3.5900/ 1
  • Ask / Lots
    3.7500/ 1
  • Open / Previous Close
    3.6200 / 3.6100
  • Day Range
    Low 3.6200
    High 3.7050
  • 52 Week Range
    Low 2.7650
    High 4.6000
  • Volume
    141,116
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 3.61
TimeVolumeAVIR
09:32 ET11513.65
09:34 ET14003.65
09:38 ET113003.665
09:39 ET1003.68
09:41 ET19003.68
09:43 ET1903.68
09:45 ET5003.685
09:48 ET7003.68
09:50 ET1003.685
09:52 ET2003.685
09:54 ET23243.685
09:56 ET1003.685
09:57 ET9003.685
10:01 ET28583.69
10:06 ET3003.685
10:08 ET9003.695
10:10 ET6003.695
10:12 ET10003.695
10:14 ET3003.695
10:15 ET2003.695
10:19 ET17913.7
10:24 ET1003.705
10:26 ET18003.7
10:28 ET1003.705
10:30 ET3333.695
10:32 ET5613.696
10:33 ET9003.7
10:35 ET7003.695
10:37 ET1003.7
10:39 ET1003.7
10:44 ET11003.7
10:48 ET4083.695
10:53 ET1003.7
11:02 ET1003.7
11:04 ET3003.695
11:06 ET2003.695
11:08 ET1003.695
11:13 ET1003.7
11:15 ET2003.7
11:20 ET1003.695
11:22 ET33003.695
11:29 ET2003.685
11:31 ET5003.69
11:36 ET11003.695
11:38 ET2483.695
11:40 ET7003.685
11:42 ET6003.69
11:44 ET1003.69
11:49 ET3003.69
11:58 ET1003.7
12:00 ET7003.695
12:02 ET4003.695
12:03 ET1213.7
12:07 ET1003.695
12:12 ET1003.695
12:14 ET4273.685
12:16 ET2003.695
12:20 ET1113.695
12:25 ET6903.695
12:27 ET5003.6971
12:32 ET1003.7
12:38 ET8083.695
12:41 ET1003.7
12:45 ET2003.695
12:50 ET13133.696
12:57 ET1003.695
12:59 ET1003.695
01:03 ET2003.6991
01:06 ET1003.695
01:08 ET2003.695
01:10 ET10003.695
01:12 ET1423.7
01:14 ET2003.695
01:17 ET1003.695
01:19 ET8003.69
01:35 ET1003.69
01:37 ET1003.685
01:42 ET1003.685
01:44 ET2003.685
01:46 ET1003.6825
01:51 ET1003.685
01:53 ET2003.69
01:55 ET4403.685
02:04 ET3703.685
02:06 ET11003.6805
02:09 ET5003.69
02:11 ET14703.68
02:13 ET44283.65
02:15 ET1003.65
02:20 ET1003.655
02:31 ET1003.655
02:36 ET2003.65
02:40 ET1003.655
02:42 ET1003.66
02:44 ET1003.655
02:47 ET2203.655
02:51 ET1003.66
02:54 ET29743.655
02:56 ET3003.65
02:58 ET2003.65
03:00 ET1003.655
03:03 ET1003.655
03:05 ET1003.655
03:07 ET2013.66
03:14 ET2003.655
03:18 ET1003.655
03:20 ET5663.65
03:23 ET4003.655
03:32 ET1003.65
03:36 ET3003.655
03:38 ET1003.65
03:39 ET19393.655
03:41 ET8993.655
03:43 ET11003.655
03:45 ET2083.655
03:50 ET3003.655
03:52 ET4003.66
03:54 ET27203.67
03:56 ET24903.66
03:57 ET3003.66
03:59 ET15843.67
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAVIR
Atea Pharmaceuticals Inc
309.1M
-1.9x
---
United StatesSLDB
Solid Biosciences Inc
317.0M
-2.1x
---
United StatesEPIX
ESSA Pharma Inc
299.5M
-10.7x
---
United StatesINZY
Inozyme Pharma Inc
298.1M
-3.5x
---
United StatesQTTB
Q32 Bio Inc
304.5M
-1.0x
---
United StatesANRO
Alto Neuroscience Inc
321.5M
-6.3x
---
As of 2024-06-01

Company Information

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is also conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). The bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy, but it is also exploring the effect of combination therapy in a smaller sub-set of patients.

Contact Information

Headquarters
225 Franklin Street, Suite 2100BOSTON, MA, United States 02110
Phone
857-204-8109
Fax
302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer, Founder
Jean-Pierre Sommadossi
Chief Financial Officer, Executive Vice President - Legal , Secretary
Andrea Corcoran
Executive Vice President, Chief Accounting Officer
Wayne Foster
Chief Development Officer
Janet Hammond
Chief Medical Officer
Maria Horga

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$309.1M
Revenue (TTM)
$0.00
Shares Outstanding
84.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.19
EPS
$-1.96
Book Value
$6.65
P/E Ratio
-1.9x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.